New FDA moves are boosting American jobs and protecting our medicine supply

For decades, U.S. policymakers have highlighted the vulnerabilities of relying on foreign supply chains for essential medicines. Yet over 70% of the primary manufacturing facilities for prescriptions filled in the United States remain outside our borders. Over time, a suffocating web of state and federal regulations meant that companies investing millions or billions to build facilities in the U.S. would see those investments sit idle for up to 14 months waiting for standard post-construction reviews.